ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions
View by Date

Monday, November 9, 2020

9:00AM-11:00AM
Abstract Number: 1870
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA
9:00AM-11:00AM
Abstract Number: 1877
Diagnosis of Axial Spondyloarthritis: A Primary Unmet Educational Need for Rheumatologists Is Interpretation of MRI
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA
9:00AM-11:00AM
Abstract Number: 1539
Diagnostic Value of Ultrasound Halo Count and Halo Score in Giant Cell Arteritis: A Retrospective Study from Routine Care
Imaging of Rheumatic Diseases Poster
9:00AM-11:00AM
Abstract Number: 1874
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA
9:00AM-11:00AM
Abstract Number: 1787
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
9:00AM-11:00AM
Abstract Number: 1851
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
9:00AM-11:00AM
Abstract Number: 1529
Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
Cytokines & Cell Trafficking Poster
9:00AM-11:00AM
Abstract Number: 1884
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA
9:00AM-11:00AM
Abstract Number: 1714
Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease
9:00AM-11:00AM
Abstract Number: 1764
Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single-center Mixed Methods Study
Reproductive Issues in Rheumatic Disorders Poster
9:00AM-11:00AM
Abstract Number: 1571
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Immunological Complications of Therapy Poster
9:00AM-11:00AM
Abstract Number: 1811
Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
9:00AM-11:00AM
Abstract Number: L05
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Late-Breaking Posters
9:00AM-11:00AM
Abstract Number: 1907
DNASE1L3 R206C Polymorphism, a Systemic Sclerosis Risk Factor, Causes Impaired Digestion of Genomic DNA in Apoptosis-derived Extracellular Vesicles
Systemic Sclerosis & Related Disorders – Basic Science Poster
9:00AM-11:00AM
Abstract Number: 1657
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
Osteoarthritis – Clinical Poster II
  • «Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 36
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology